文献速递淋巴瘤

甲状腺激素促进JAK/STAT通路异常激活并推动T细胞淋巴瘤播散

Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination.
PubMed 文献 · Blood Adv · 2025-01-01

该研究探讨甲状腺激素(THs)对T细胞淋巴瘤(TCL)JAK/STAT通路的影响及治疗意义。THs通过整合素αvβ3激活STAT1、3、5并上调靶基因和金属蛋白酶活性;整合素αvβ3抑制剂西仑吉肽可逆转这些效应,与贝沙罗汀联用较JAK1/2抑制剂芦可替尼联合贝沙罗汀抗淋巴瘤活性更强;临床前模型显示该联合方案减少肿瘤STATs磷酸化、基质金属蛋白酶活性和转移灶数目;TCL患者样本中整合素αvβ3 mRNA高表达富集于淋巴瘤进展相关通路并降低总生存。

要点

  • 甲状腺激素经整合素αvβ3激活TCL细胞STAT1、3、5并上调靶基因和金属蛋白酶活性。
  • 西仑吉肽可逆转THs效应,与贝沙罗汀联用抗淋巴瘤活性强于芦可替尼联合贝沙罗汀。
  • TCL患者样本中整合素αvβ3 mRNA高表达富集于淋巴瘤进展通路并降低总生存。

核心结论

  • 作者认为靶向甲状腺激素信号(通过抑制整合素αvβ3)联合贝沙罗汀是一种毒性较低的治疗策略,可能减轻JAK/STAT异常激活并限制淋巴瘤播散。

研究设计与样本

  • 研究采用TCL细胞实验、临床前TCL体内模型和蛋白质组学分析,并检测TCL患者样本中整合素αvβ3 mRNA水平与通路及总生存的关系。

主要发现

  • 甲状腺激素诱导STAT1、3和5激活,包括上调靶基因和金属蛋白酶活性。
  • 整合素αvβ3抑制剂西仑吉肽不仅逆转上述效应,与贝沙罗汀联用时抗淋巴瘤活性强于JAK1/2抑制剂芦可替尼联合贝沙罗汀。
  • 西仑吉肽与贝沙罗汀联合方案在临床前TCL体内模型中显著降低肿瘤STATs磷酸化、基质金属蛋白酶活性和转移灶数目,并调节参与细胞增殖、血管生成、代谢和免疫应答的蛋白。
  • TCL患者样本中整合素αvβ3信使RNA高表达富集于淋巴瘤进展相关通路,并降低总生存。

临床怎么用

  • 作者认为通过抑制整合素αvβ3靶向甲状腺激素信号联合贝沙罗汀具有治疗潜力,可作为减轻JAK/STAT异常激活和限制淋巴瘤播散的毒性较低策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Abnormal JAK/STAT pathway activation is widespread in virtually all T-cell lymphoma (TCL) subtypes. However, activating mutations are insufficient to drive leukemic cell proliferation, which also requires enhanced upstream signaling. We have described that thyroid hormones (THs) contribute to the malignant phenotype of TCL by inducing intracellular transcriptional programs through integrin αvβ3 activation. Here, we evaluate the effect of THs on the JAK/STAT pathway and its implications on TCL therapy. We found that THs induce the activation of STAT1, 3, and 5, including the upregulation of target genes and metalloprotease activity. Furthermore, we observed that the integrin αvβ3 inhibitor, cilengitide, not only reverts these effects but also enhances the antilymphoma activity to a greater extent than the JAK1/2 inhibitor, ruxolitinib, when combined with bexarotene, a synthetic rexinoid clinically used for cutaneous TCL treatment. Furthermore, we explored the mechanisms of action of cilengitide and bexarotene combination using preclinical TCL in vivo models and proteomic analysis. We found that this combinatorial protocol significantly reduced tumor STATs phosphorylation, matrix metalloproteinase activity, and the number of metastatic foci by regulating proteins involved in cell proliferation, angiogenesis, metabolism, and immune response. In addition, we observed that high integrin αvβ3 messenger RNA levels are enriched in pathways associated with lymphoma progression and reduce overall survival in samples from patients with TCL. Our findings support the therapeutic potential of targeting THs signaling through integrin αvβ3 inhibition in combination with bexarotene as a less toxic therapeutic strategy to mitigate aberrant JAK/STAT activation and limit lymphoma dissemination.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Debernardi M, Correa A, Alvarado L, et al. Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination. Blood Adv. 2025. PMID: 40489893. doi:10.1182/bloodadvances.2024015332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。